Q&A with ADLM 2025 Annual Meeting Organizing Committee Chair

Laboratory developed tests (LDTs) and their regulation have certainly seen a lot of change. While LDT regulations are paused for now under the current administration, their long term future remains uncertain. To that end, we’re planning a session that delves into the advocacy efforts around regulation.

 

As ADLM grows, the content of the meeting is expanding too. We had submissions this year for sessions related to microbiology and hematology and coagulation, so you can see that those topics are maturing within our organization.

Why is it critical for the lab medicine community to collaborate at this type of meeting?
These days, most research projects require a cross-disciplinary team of collaborators who can learn — and apply — new information. Because your team may need to rely on people outside of your expertise to do that, it is important to identify people who bring additional knowledge and skills to help you solve problems.

Do you have a specific goal for ADLM 2025?
I want to bring new voices into the meeting. During my time leading AMOC, I made sure that we tapped into new talent with new ideas. And I’m pleased to report that we have a very diverse slate of speakers this year — not only for the plenaries but also for the scientific sessions and university courses that are new to the meeting.

Will ADLM 2025 appeal to people who aren’t clinical laboratorians?